

Cystic Fibrosis Committee meeting 13

Date: 19/10/2016

Location: Hodgkin Building, Guy's Campus.

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Martin Walshaw		(Present for notes 1 – 9)
Elaine Edwards		(Present for notes 1 – 9)
Iolo Doull		(Present for notes 1 – 9)
Sarah Collins		(Present for notes 1 – 9)
Alexander Darlington		(Present for notes 1 – 9)
Zoe Elliott		(Present for notes 1 – 9)
Janis Bloomer		(Present for notes 1 – 9)
David Lacy		(Present for notes 1 – 9)
Mandy Bryon		(Present for notes 1 – 9)
Andrew Jones		(Present for notes 1 – 9)
Keith Thompson		(Present for notes 1 – 9)
Stuart Elborn		(Present for notes 1 – 9)

In attendance:		
Andrew Gyton	NICE Commissioning Manager	(Present for notes 1 – 9)
Vanessa Delgado Nunes	NGA Guideline Lead	(Present for notes 1 – 9)
Stephen Murphy	NGA Clinical Advisor	(Present for notes 1 – 9)
Fionnuala O'Brien	NGA Project Manager	(Present for notes 1 – 9)
Gemma Villanueva	NGA Systematic Reviewer	(Present for notes 1 – 9)
Gemma Marceniuk	NGA Health Economist	(Present for notes 1 – 5)
Rami Cosulich	NGA Assistant Systematic Reviewer	(Present for notes 1 – 9)
Bishal Bhandari	NGA Assistant Systematic Reviewer	(Present for notes 1 – 9)
Annabel Flint	NGA Project Manager	(Present for notes 1 – 5)

Apologies:	
Sarah Popple	Committee member
Helen Parrott	Committee member
Nichola MacDuff	Committee member
Helen McCabe	Committee member
Thomas Feist	NICE Guideline Coordinator

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the thirteenth guideline committee meeting on Cystic Fibrosis. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received and these are noted above.

The Chair outlined the objectives of the meeting, which included:

- The presentation of the health economics model – what is the clinical and cost effectiveness of immunomodulatory agents in the management of lung disease.
- Evidence review on bone mineral density and recommendations and linking evidence to recommendations
- Evidence review on information and support, and recommendation and linking evidence to recommendations
- Review of recommendations to date.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the immunomodulatory agents, bone mineral density and information and support in relation to Cystic Fibrosis.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Iolo Doull	Consultant Respiratory Paediatrician, Children's Hospital for Wales, Cardiff	Gave a talk to GPs about asthma which was sponsored by Astrazeneca. Was paid	Personal financial, non-specific	Declare and participate

		<p>directly. Astrazeneca do not manufacture any products discussed in this guideline or for the treatment of CF. 20.10.2016</p>		
--	--	---	--	--

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee whether any changes were required to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Gemma Marceniuk who gave a presentation on Health Economic Model - What is the clinical and cost effectiveness of immunomodulatory agents in the management of lung disease and took questions from the Committee.

The Chair introduced Gemma Villanueva who gave a presentation titled “Evidence review on bone mineral density”.

Vanessa Delgado Nunes, Guideline Lead, led the Committee through the process of drafting recommendations for the topic of bone mineral density.

The Chair introduced Gemma Villanueva who gave a presentation titled “Evidence review on information and support”.

Vanessa Delgado Nunes, Guideline Lead, led the Committee through the process of drafting recommendations for information and support.

The Committee thanked everyone for their presentations and contribution to the development of the guideline.

5. Questions and discussion

The Committee asked questions on the presentations and the Chair then led the Committee through the process of drafting recommendations and LETRs from the evidence reviews.

Martin Walshaw, the Chair, Vanessa Delgado Nunes, Guideline Lead and Stephen Murphy, Clinical Advisor, led the Committee through the recommendations made to

date.

6. Any other business

There were no other items of business. The chair thanked the Committee for attending and closed the meeting.

Date of next meeting: 23/11/2016

Location of next meeting: Hodgkin Building, Guy's Campus